Actively Recruiting
I.V Papavrine for Labor Induction in Term PROM
Led by Western Galilee Hospital-Nahariya · Updated on 2026-04-08
110
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo
CONDITIONS
Official Title
I.V Papavrine for Labor Induction in Term PROM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Singleton pregnancy
- Term gestation between 37 and 42 weeks
- Term PROM prior to active labor
- Duration of PROM less than 12 hours at enrollment
- Bishop score less than 8
- Cephalic presentation
- Viable fetus with reassuring fetal heart rate
You will not qualify if you...
- Multiple gestation
- Previous cesarean delivery
- Major fetal anomalies
- Contraindication to vaginal delivery
- Meconium-stained amniotic fluid
- Suspected chorioamnionitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Galilee Medical Center
Nahariya, Israel, Israel
Actively Recruiting
Research Team
M
Maya Frank Wolf, professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here